These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32661269)

  • 21. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
    Sueta D; Yamamoto E; Tsujita K
    Curr Hypertens Rep; 2020 Feb; 22(3):21. PubMed ID: 32114686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review.
    Janković SM; Janković SV
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):291-308. PubMed ID: 35190999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
    Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
    J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
    Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
    Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
    Arai K; Tsuruoka H; Homma T
    Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists.
    Xu X; Feng J; Cui Y; Li P; Dong J; Liao L
    J Diabetes; 2024 Jun; 16(6):e13566. PubMed ID: 38753662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.
    Okuda Y; Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Sawanobori T; Taguri M
    Hypertens Res; 2023 Feb; 46(2):437-444. PubMed ID: 36100672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study.
    Itoh H; Ito S; Rakugi H; Okuda Y; Nishioka S
    Hypertens Res; 2019 Oct; 42(10):1572-1581. PubMed ID: 31239535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
    Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
    Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Antihypertensive Effects of Esaxerenone with the Internal Sodium Balance in Dahl Salt-Sensitive Hypertensive Rats.
    Hattori M; Rahman A; Kidoguchi S; Jahan N; Fujisawa Y; Morisawa N; Ohsaki H; Kobara H; Masaki T; Hossain A; Steeve A; Nishiyama A
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, Metabolism, and Excretion of [
    Yamada M; Mendell J; Takakusa H; Shimizu T; Ando O
    Drug Metab Dispos; 2019 Mar; 47(3):340-349. PubMed ID: 30541878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
    Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
    Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
    Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
    Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism.
    Ishikawa T; Morimoto S; Ichihara A
    Hypertens Res; 2022 Mar; 45(3):496-506. PubMed ID: 34961793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
    Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
    Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.